Category: Bayer HealthCare
Here's a look at some of the top Wall Street stories for medical device companies this week: Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?; M&A: Medtech makers use acquisitions to fill niches; Report: Deals in the medical device sector rose 200% in Q1; CareFusion plans $1B debt offering; Activist investor Oracle revives proxy war at Biolase.
Cardiovascular Systems' shares drop as Boston Scientific positions itself as a peripherals market rival with the $415 million acquisition of Bayer AG's interventional business.
Boston Scientific's (NYSE:BSX) $415 million acquisition of Bayer AG's interventional unit is a strong move for the company, but it may bode ill for other peripheral players.
Boston Scientific agrees to a $415 million deal to add Bayer's interventional business to its peripheral interventions unit, adding thrombectomy and atherectomy devices to its portfolio.
Boston Scientific (NYSE:BSX) said it agreed to acquire Bayer AG's interventional unit for $415 million, in a move to significantly bolster its own $200 million peripheral interventions business.
Women rallying against the Essure contraceptive implant are congregating online and picketing on street corners, calling on Bayer to recall the device.
MASSDEVICE ON CALL — The anti-Essure movement, launched by women who claim the permanent contraceptive implant left them with severe pain and injuries, doesn't look likely to die down, having spawned Facebook support pages, Twitter campaigns and lots of media attention.
The movement has attached itself to the Twitter hashtag '#EssureRally', through which women are calling on Bayer to recall the device, posting pictures of the ralliers in action and organizing real-world events, including street-corner picketing and conference calls with famed consumer advocate Erin Brockovich.
GlobalData analyst Joseph Gregory says public advocate Erin Brockovich's patient safety claims against Bayer's Essure contraceptive implant are "inappropriate" and "unsubstantiated."
Bayer's Contour Next Link blood glucose meter is the 1st U.S.-cleared device that pairs with Medtronic's newly approved 'artificial pancreas', the MiniMed 530G with Enlite diabetes management system.
The FDA says its additional review suggests Bayer's Essure permanent birth control device isn't connected to rising patient reports of post-treatment weight-gain, depression and fatigue.
It looks like healthcare giant Bayer (PINK:BAYRY) has got the FDA in its corner against a rising tide of patient complaints over the company's Essure permanent birth control device.